Supplementary Table 1. Genetic characteristics of founder variant(s).

			W	G		env diversity ³			
Pub-id	WG	HG ¹	InSites	Cons. ²	n	Mean	Min.	Max.	Treatment
502-0006	0	1	n.a.	1	0	n.a.	n.a.	n.a.	Placebo
502-0053	10		0	1	10	0.001	0	0.0041	Placebo
502-0062	6		2	1	6	0.0008	0	0.0015	Vaccine
502-0176	11	1	13	1	11	0.0022	0	0.0044	Placebo
502-0223	1		n.a. 397	1 2	1 11	n.a. 0.0314	n.a. 0	n.a.	Placebo Vaccine
502-0227 502-0287	11 4	1	1	1	4	0.0314	0.0007	0.058 0.0015	Vaccine
502-0207 502-0309°	5	'	0	1	5	0.0011	0.0007	0.0010	Vaccine
502-0322	3	2	0	1	5	0.0006	0	0.0015	Placebo
502-0341	7 9		2	1	7	0.0008	0	0.0015	Vaccine
502-0346				1	9	0.0008	0	0.0029	Placebo
502-0364	5	4	0 1	1 1	5 9	0.0003 0.0005	0	0.0007 0.0022	Placebo
502-0388 502-0491	5 4	4	2	1	4	0.0003	0	0.0022	Placebo Vaccine
502-0524	10		5	1	10	0.0027	0	0.0022	Vaccine
502-0525	5		1	1	5	0.0003	0	0.0007	Placebo
502-0572	5		0	1	5	0.0003	0	0.0007	Placebo
502-0648	4		1	1	4	0.0004	0	0.0007	Vaccine
502-0717	6		0	1	6	0.0002	0	0.0007	Placebo
502-0762 502-0823	10 7		2 1	<u>1</u> 1	9 7	0.0006 0.0002	<u>0</u>	0.0022 0.0007	Vaccine
502-0823	12		103	2	12	0.0002	0	0.0007	Vaccine Vaccine
502-0841	4		4	1	4	0.0029	0.0022	0.0037	Vaccine
502-0879°	5		13	2	5	0.0003	0	0.0007	Vaccine
502-0897	10		10	1	10	0.0016	0	0.0044	Vaccine
502-0923	8		0	1	8	0.0002	0	0.0009	Placebo
502-0938	4	6	9	1	10	0.0019	0	0.0066	Placebo
502-0961 502-0965	11 2	1 2	3 59	2 2	12 4	0.0005 0.0141	0	0.0022 0.0261	Vaccine Placebo
502-0965	10	2	23	2	10	0.0026	0	0.0261	Placebo
502-1046	5		0	<u>-</u>	5	0.0003	0	0.0007	Vaccine
502-1047	5		4	1	5	0.0006	0	0.0015	Placebo
502-1055	2	4	0	1	6	0.0002	0	0.0007	Vaccine
502-1115 ^b	4		4	1	4	0.0028	0.0015	0.0037	Placebo
502-1174	10		114	2	10 5	0.0011 0.0037	0.0029	0.0029 0.0051	Vaccine
502-1191 502-1211	5 5		4	1	5	0.0037	0.0029	0.0031	Vaccine Vaccine
502-1211	2	1	0	1	2	0.0005	0.0015	0.0007	Vaccine
502-1399	5		40	2	5	0.0051	0.0015	0.0095	Vaccine
502-1400	5		0	1	5	0.0006	0	0.0015	Vaccine
502-1478	5		0	1	5	0	0	0	Placebo
502-1500	3	1	2	1	4	0.0018	0.0007	0.0029	Vaccine
502-1504 ^d 502-1512	9 11		55 24	2 1	8 11	0.0067 0.0022	0	0.026 0.0051	Placebo Vaccine
502-1512	10		29	2	10	0.0022	0	0.0031	Placebo
502-1619	10		45		10	0.0036	0	0.0103	Vaccine
502-1709	5		74	2	11	0.0154	0.0007	0.0543	Vaccine
502-1799	5		2	1	5	0.0004	0	0.0007	Placebo
502-1897	5		0	1	5	0	0	0	Vaccine
502-1919 502-1926	0 8	<u>1</u>	n.a. 2	<u>1</u> 1	1 8	n.a. 0.0018	n.a. 0	n.a. 0.0066	Placebo Vaccine
502-1926	9	1	20	1	10	0.0018	0.0007	0.0059	Vaccine
502-2008	10		98	2	10	0.0104	0.0029	0.0192	Placebo
502-2136	5		0	1	5	0.0009	0	0.0022	Vaccine
502-2241	11		18 2	1 1	11	0.0022	0	0.0051	Vaccine
502-2254	6		2		6	0.0033	0.0015	0.0051	Vaccine
502-2289	5	2	4	1	5	0.0028	0	0.0051	Vaccine
502-2305 502-2349	11 4	3	127 1	4 1	14 4	0.0047 0.0019	0	0.0088 0.0037	Vaccine Vaccine
502-2349	10	2	0		10	0.0019	0	0.0037	Vaccine
502-2495	3	-	0	11	3	0.0001	0	0.0007	Placebo
502-2586	6	2	15	2	6	0.0045	0.0015	0.0074	Placebo
502-2622	5		16	1	5	0.0032	0.0015	0.0044	Placebo
502-2649	9		36	2	9	0.0015	0	0.0037	Vaccine
502-2667	5		<u> </u>	<u>1</u> 1	5 6	0.0006	0 0	0.0015	Placebo
502-2696° 502-2717	6 6	1 1	1	1	6 7	0.001 0.0012	0	0.0029 0.0029	Vaccine Vaccine
502-2717	5	'	0	1	5	0.0012	0	0.0029	Placebo
552 2754	J		0	'	3	5.00 IL	J	0.0020	30000

- ¹ Number of additional half-genome sequences.
- Number of consensus founder variant(s).
- Nucleotide pairwise sequence diversity (Mean and minimum and maximum).
- ^a Possible transmission linkage with another volunteer.
- b Female volunteer.
- ^c Recombinant CRF02_AG isolate.
- d No HLA- genotype data available.